

NEWS RELEASE



Veritas In Silico



November 11, 2025

Company Name: **Veritas In Silico Inc.**

Representative: Shingo NAKAMURA,

Representative Director and CEO

Listed on: TSE Growth

Stock Ticker Code: 130A

Contact Person: Tsuneo GODA,

Executive Officer, General Manager,

Corporate Planning Division

Email: ir@veritasinsilico.com

Organizational Reforms and Personnel Changes

Veritas In Silico Inc. announces that the Board of Directors passed the resolutions at a meeting held today, regarding the organizational reforms and assignment of General Manager, effective January 1, 2026.

■ Purpose and Details of Organizational Reforms


The Company is dedicated to the discovery of novel mRNA targeted small molecule drugs and nucleic acid therapeutics, while concurrently advancing initiatives aimed at breakthroughs in the healthcare field, such as the development of new therapies and drug delivery methods. The Company is establishing a "Corporate Venture Office" to sequentially commercialize projects that achieve sufficient progress in the healthcare field going forward. Through the strategic decision, it is expected to enhance shareholder value over the medium to long term.

■ Personnel assign for General Manager positions

Name	Responsibilities as of January 1, 2026	Current Responsibilities
Jun SASAKI	General Manager of Corporate Venture Office	(New Hires)

(For reference)

Organization Chart as of January 1, 2025



Note: The red lines and red underlined text indicate the revised parts.

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.